Account

Table 2 Observed responses (mean) in 2⁴ full factorial design for HVD-NLCs

From: Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation

Formula code	Factors				Responses
Formula code	A	B	C	D	PS (nm)	PDI	ZP (mV)	EE (%)
VER-1	20	270	15	200	207.33 ± 5.68	0.562 ± 0.019	− 37.5 ± 1.17	74.35 ± 4.00
VER-2	30	270	15	200	183.7 ± 5.38	0.629 ± 0.012	− 40.4 ± 1.31	61.01 ± 3.06
VER-3	20	285	15	200	204.5 ± 3.078	0.556 ± 0.049	− 43.8 ± 1.35	77.63 ± 9.36
VER-4	30	285	15	200	189.86 ± 3.76	0.546 ± 0.049	− 43.7 ± 1.31	83.15 ± 6.08
VER-5	20	270	30	200	203.06 ± 4.65	0.409 ± 0.052	− 45.9 ± 2.71	72.33 ± 9.64
VER-6	30	270	30	200	209.5 ± 3.47	0.327 ± 0.037	− 47.5 ± 2.45	72.08 ± 3.95
VER-7	20	285	30	200	201.46 ± 2.36	0.383 ± 0.029	− 49.1 ± 0.953	76.48 ± 17.81
VER-8	30	285	30	200	182.6 ± 6.95	0.382 ± 0.022	− 48.1 ± 1.36	67.11 ± 5.37
VER-9	20	270	15	300	188.4 ± 4.9	0.462 ± 0.043	− 49.1 ± 1.55	97.21 ± 1.615
VER-10	30	270	15	300	170.73 ± 5.53	0.526 ± 0.03	− 45.6 ± 1.17	91.71 ± 9.19
VER-11	20	285	15	300	190.3 ± 8.22	0.451 ± 0.033	− 46.7 ± 1.7	98.81 ± 1.012
VER-12	30	285	15	300	167.96 ± 1.76	0.589 ± 0.101	− 44.5 ± 3.5	84.56 ± 0.162
VER-13	20	270	30	300	173.46 ± 0.75	0.501 ± 0.019	− 46.7 ± 1.13	93.95 ± 4.10
VER-14	30	270	30	300	157.46 ± 3.61	0.429 ± 0.023	− 49.6 ± 2.39	79.86 ± 1.15
VER-15	20	285	30	300	178.36 ± 2.65	0.489 ± 0.048	− 48.1 ± 1.58	95.39 ± 2.16
VER-16	30	285	30	300	162.86 ± 3.35	0.436 ± 0.031	− 49.4 ± 1.08	77.88 ± 2.78

A homogenization time (min), B solid lipid concentration (mg), C liquid lipid concentration (mg), D surfactant concentration (mg), PS particle size, PDI polydispersity index, ZP zeta potential, EE entrapment efficiency

Back to article page